On September 7th, the "41st National Pharmaceutical Industry Information Annual Conference and the 2023 China Pharmaceutical Industry Top 100 List Release Ceremony," hosted by the China Pharmaceutical Industry Information Center, guided by the China Academy of Pharmaceutical Industry Research, and undertaken by the Sichuan Provincial Department of Economy and Information Technology, opened in Chengdu. The highly anticipated 2023 China Pharmaceutical Industry Top 100 list was released during the conference, with Dongfuron ranking at 69th place.

 

 

The "China Pharmaceutical Industry Top 100 List" reflects the economic performance of China's pharmaceutical industry and serves as an important barometer for the industry. The selection and ranking process involves multiple rigorous reviews, including preliminary material screening, multiple rounds of expert reviews by the Ministry of Industry and Information Technology (MIIT), and comprehensive evaluation. Companies that make it to the top 100 are leaders in the pharmaceutical industry, representing the highest level of China's pharmaceutical manufacturing.

 

 

Dongfuron drives its development through innovation, striving to build a hub for talent and innovation. It has made significant investments and actively laid out strategies in cutting-edge fields such as complex formulations and synthetic biology. It has also received multiple official recognitions, including the National Enterprise Technology Center and the 2023 Shanghai Municipal Design Innovation Center. Over the past 30 years, Dongfuron has adhered to a "customer-centric" approach, serving over 3,000 pharmaceutical companies and earning a good reputation. Its ranking on the 2023 China Pharmaceutical Industry Top 100 list is the best recognition from customers and the market.

 

 

Dongfuron actively deploys new drug manufacturing platforms to meet the development needs of the pharmaceutical industry. It continuously explores the science of pharmaceutical machinery manufacturing and drug manufacturing, aiming to create the next-generation drug manufacturing platform. By reducing production costs for pharmaceutical companies, ensuring drug safety, and facilitating rapid product launches, Dongfuron provides more options for China's and the global pharmaceutical industry.